

News Release

Takeda Pharmaceutical Company Limited
AstraZeneca K.K.
Mitsubishi Tanabe Pharma Corporation
Eisai Co., Ltd.

***Helicobacter pylori* Gastritis Approved as Additional Indication in Japan for *Helicobacter pylori* Eradication by Triple Therapy with Proton Pump Inhibitor**

Osaka and Tokyo, Japan, February 21, 2013 --- Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President & CEO: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) jointly announced today that *Helicobacter pylori* (“*H. pylori*”) gastritis has been approved by Japan’s Ministry of Health, Labour and Welfare as an additional indication for *H. pylori* eradication by triple therapy with proton pump inhibitors. This therapy consists of a proton pump inhibitor^{*1}, amoxicillin hydrate^{*1}, and either clarithromycin^{*1} or metronidazole^{*1}.

H. pylori gastritis is a histological gastric mucosal injury caused by the persistent infiltration of inflammatory cells in the gastric mucosa due to *H. pylori* infection, and is believed to be associated with the development of diseases such as gastric and duodenal ulcers. Existing indications approved for reimbursement under Japan’s National Health Insurance (NHI) for *H. pylori* eradication were limited to gastric and duodenal ulcers, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and the stomach after endoscopic resection of early-stage gastric cancer. Against this backdrop, the respective presidents of the Japanese Society of Gastroenterology, the Japan Gastroenterological Endoscopy Society, and the Japanese Society for Helicobacter Research submitted a joint letter to the Minister of Health, Labour and Welfare in December 2011 requesting the subsequent coverage under NHI of *H. pylori* gastritis as an additional indication for *H. pylori* eradication by triple therapy. In response to this, the four companies submitted a joint application in August 2012 based on the clinical evidence already published to date, together with five other companies^{*2} also seeking additional indication approval for each drug.

The four companies expect the approval of this additional indication to significantly contribute to the prevention and treatment of diseases related to *H. pylori*.

###

^{*1} For a full list of products, please refer to “Notes for Editors” below.

^{*2} The joint applicants of the additional indication also include five other companies marketing amoxicillin hydrate, clarithromycin and metronidazole: Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Abbott Japan Co., Ltd., Shionogi & Co., Ltd. and Taisho Pharmaceutical Co., Ltd. Mylan Inc., Ohara Pharmaceutical Co., Ltd. and Takata Seiyaku Co., Ltd. submitted their respective applications for the additional indication of their drugs in December 2012.

###

Notes for Editors

The approved products included in the application are as follows: (generic name) and <name of manufacturer>

1. Proton Pump Inhibitors

- Takepron[®] Capsules 15 and 30; Takepron[®] OD Tablets 15 and 30 (lansoprazole) <Takeda Pharmaceutical Company Limited>
- Omepral[®] Tablets 10 and 20 (omeprazole) <AstraZeneca K.K.>
- Omeprazon[®] Tablets 10 mg and 20 mg (omeprazole) <Mitsubishi Tanabe Pharma Corporation>
- Pariet[®] Tablets 10 mg (rabeprazole sodium) <Eisai Co., Ltd.>
- Nexium[®] Capsules 10 mg and 20 mg (esomeprazole magnesium hydrate) <AstraZeneca K.K. (sales and distribution by Daiichi Sankyo Co., Ltd.)>
- Omeprazole Tablets “Mylan” 10 mg and 20 mg (omeprazole) <Mylan Inc.>
- Rabeprazole Na Tablets “Ohara” 10 mg (rabeprazole sodium) <Ohara Pharmaceutical Co., Ltd.>

2. Amoxicillin Hydrates

- Pasetocin[®] Capsules 125 and 250; Pasetocin[®] Tablets 250 <Kyowa Hakko Kirin Co., Ltd.>
- Sawacillin[®] Capsules 125 and 250; Sawacillin[®] Tablets 250 <Astellas Pharma Inc.>
- Amolin[®] Capsules 125 and 250; Amolin[®] Granules 10% <Takeda Pharmaceutical Company Limited>

3. Clarithromycin Products

- Clarith[®] Tablets 200 <Taisho Pharmaceutical Co., Ltd. (Marketed by: Taisho Toyama Pharmaceutical Co. Ltd.)>
- Klaricid[®] Tablets 200 mg <Abbott Japan Co., Ltd.>
- Clarithromycin Tablets “Mylan” 200 mg <Mylan Inc.>
- Clarithromycin Tablets “Takata” 200 mg < Takata Seiyaku Co., Ltd. >

4. Metronidazole Products

- Flagyl[®] Oral Tablets 250 mg <Shionogi & Co., Ltd.>

5. Combination Packages

- Lansap[®] 400; Lansap[®] 800 <Takeda Pharmaceutical Company Limited>
- Lampion[®] Pack <Takeda Pharmaceutical Company Limited>

###

Media Contacts:

Takeda Pharmaceutical Company Limited

Corporate Communications Department TEL: +81-3-3278-2037

AstraZeneca K.K.

Corporate Communications, Corporate Affairs TEL: +81-6-6453-8011

Mitsubishi Tanabe Pharma Corporation

Corporate Communications Department TEL: +81-6-6205-5211

Eisai Co., Ltd.

Public Relations Department TEL: +81-3-3817-5120

###